ASH 2024: Global Updates in the Management of Chronic Lymphocytic Leukemia - Episode 5

Clinical Insights and Real-World Evidence

, , ,

Panelists discuss, which patients are favored for the Venetoclax-Obinutuzumab treatment approach.

Video content above is prompted by the following:

  • In which patients would you favor the Venetoclax-Obinutuzumab treatment approach?